This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Zimmerer, J. M. Articles by Carson, W. E. Search for Related Content PubMed PubMed Citation Articles by Zimmerer, J. M. Articles by Carson, W. E., III

Gene Expression Profiling Reveals Similarities between the In vitro and In vivo Responses of Immune Effector Cells to IFN-

Authors' Affiliations: ¹ Integrated Biological Sciences Graduate Program, ² Human Cancer Genetics Program, Department of Molecular Virology, Immunology, and Medical Genetics, ³ Department of Internal Medicine, ⁴ Center for Biostastistics, and ⁵ Department of Surgery, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Requests for reprints: William E. Carson III, Department of Surgery, The Ohio State University, N924 Doan Hall, 410 West 10th Avenue, Columbus, OH 43210. Phone: 614-293-6306; Fax: 614-293-3465; E-mail: william.carson{at}osumc.edu.

Purpose: The precise molecular targets of IFN- therapy in the context of malignant melanoma are unknown but seem to involve signal transducers and activators of transcription 1 signal transduction within host immune effector cells. We hypothesized that the in vitro transcriptional response of patient peripheral blood mononuclear cells (PBMC) to IFN- would be similar to the in vivo response to treatment with high-dose IFN-.

Experimental Design: The gene expression profiles of PBMCs and immune cell subsets treated in vitro with IFN- were evaluated, as were PBMCs obtained from melanoma patients receiving adjuvant IFN-.

Results: Twenty-seven genes were up-regulated in PBMCs from normal donors after treatment with IFN- in vitro for 18 hours (>2-fold, P < 0.001). A subset of these genes (in addition to others) was significantly expressed in IFN-–treated T cells, natural killer cells, and monocytes. Analysis of gene expression within PBMCs from melanoma patients (n = 13) receiving high-dose IFN--2b (20 MU/m² i.v.) revealed significant up-regulation (>2-fold) of 21 genes (P < 0.001). Also, the gene expression profile of in vitro IFN-–stimulated patient PBMCs was similar to that of PBMCs obtained from the same patient after IFN- therapy.

Conclusions: This report is the first to describe the transcriptional response of T cells, natural killer cells, and monocytes to IFN- and characterize the transcriptional profiles of PBMCs from melanoma patients undergoing IFN- immunotherapy. In addition, it was determined that microarray analysis of patient PBMCs after in vitro stimulation with IFN- may be a useful predictor of the in vivo response of immune cells to IFN- immunotherapy.